Veracyte, Inc. is a global diagnostics company. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder and TrueMRD for MIBC). It has developed the noninvasive Percepta Nasal Swab test to help physicians determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas. The Company has acquired the UroAmp platform, which has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.
Back to dashboard
Company Information
About this company
Key people
Robert S. Epstein
Independent Chairman of the Board
Karin Eastham
Independent Director
Jens Holstein
Independent Director
Marc A. Stapley
Chief Executive Officer, Director
Rebecca Chambers
Chief Financial Officer
Kevin R. Haas
Chief Development and Technology Officer
Phillip G. Febbo
Chief Scientific Officer, Chief Medical Officer
Annie Mcguire
General Counsel, Head - Market Access
John Leite
Global Chief Commercial Officer
Eliav Barr
Independent Director
Muna Bhanji
Independent Director
Click to see more
Key facts
- Shares in issue80.39m
- EPICVCYT
- ISINUS92337F1075
- LocationUnited States
- SectorHealthcare
- IndustryHealthcare Facilities
- Market cap$3.31bn
- Employees755
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.